Natco Pharma gets approval for generic Daclatasvir Dihydrochloride Tablets

From Drugs Controller General (India)

Natco Pharma announced that it is the first Indian Company to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30mg & 60mg, from Drugs Controller General (India). Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.

Natco will market generic Daclatasvir under its own brand NATDAC, and through its strategic partners in India. Natco will launch immediately in India at an MRP of Rs.6000/-(Rupees Six thousand only) and Rs.4000/- (Rupees Four Thousand only) for the 60mg and 30mg strengths, respectively, for a bottle of 28 tablets.

Powered by Capital Market - Live News